{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:51:04Z","timestamp":1791838264346,"version":"4.3.4"},"reference-count":18,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Addenbrooke's Charitable Trust grant","award":["Addenbrooke's Charitable Trust grant"],"award-info":[{"award-number":["Addenbrooke's Charitable Trust grant"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Although proton pump inhibitors are the mainstay of gastroesophageal reflux disease treatment, up to 30% of patients have a poor symptomatic response. Ambulatory pH impedance monitoring is the gold standard to assess whether this is due to persistent acid reflux. We aimed to characterize clinical predictors of persistent esophageal acid reflux on proton pump inhibitors including gastric pH measured during endoscopy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We prospectively recruited patients with gastroesophageal reflux disease and\/or Barrett esophagus on proton pump inhibitors. All patients completed a symptom questionnaire and underwent gastroscopy with gastric pH analysis, immediately followed by ambulatory 24\u2010hour pH impedance. We used a modified cutoff of 1.3% for pathological esophageal acid exposure time. A multiple linear regression model was used to analyze the correlation between acid exposure time and predictive variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We recruited 122 patients, of whom 92 (75.4%) were included in the final analysis (44 male (47.8%), median age 53 years (interquartile range (IQR): 43\u201366)). Forty\u2010four patients (47.8%) had persistent acid reflux with a median total acid exposure time of 2.2% (IQR: 1.2\u20135.0), compared with 0.1% (IQR: 0.0\u20130.2) in patients without persistent reflux (<jats:italic>n<\/jats:italic>\u2009=\u200948; <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001). There was no difference in age, sex, body mass index, proton pump inhibitor regimen, diagnosis of hiatus hernia or Barrett esophagus, and severity of symptoms between patients with normal and abnormal acid exposure time. Median gastric pH was significantly lower in patients with persistent acid reflux (5.8 vs 6.6, <jats:italic>p<\/jats:italic>\u2009=\u2009.032) and it correlated with the total acid exposure time (<jats:italic>p<\/jats:italic>\u2009=\u2009.045; R<jats:sup>2\u2009<\/jats:sup>=\u200912.0%). With a pH cutoff of 5.05, single\u2010point endoscopic gastric pH analysis had an area under the receiver operating characteristic curve of 63.0% (95% confidence interval: 51.3\u201374.7) for prediction of persistent acid reflux.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Symptoms and clinical characteristics are not useful to predict persistent acid reflux in patients on proton pump inhibitors. One\u2010point gastric pH correlates with 24\u2010hour esophageal acid exposure time and could guide clinicians to assess treatment response; however, its utility needs validation in larger studies.<\/jats:p><\/jats:sec>","DOI":"10.1177\/2050640619880362","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T07:08:32Z","timestamp":1570604912000},"page":"1389-1398","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Endoscopic measurement of gastric pH is associated with persistent acid reflux in patients treated with proton pump inhibitors for gastroesophageal reflux disease"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-2661","authenticated-orcid":false,"given":"Wladyslaw","family":"Januszewicz","sequence":"first","affiliation":[{"name":"MRC Cancer Unit University of Cambridge Cambridge UK"},{"name":"Department of Gastroenterology, Hepatology and Clinical Oncology Medical Centre for Postgraduate Education Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hartley","sequence":"additional","affiliation":[{"name":"MRC Cancer Unit University of Cambridge Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Waldock","sequence":"additional","affiliation":[{"name":"MRC Cancer Unit University of Cambridge Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Roberts","sequence":"additional","affiliation":[{"name":"MRC Cancer Unit University of Cambridge Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bincy","family":"Alias","sequence":"additional","affiliation":[{"name":"MRC Cancer Unit University of Cambridge Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Hobson","sequence":"additional","affiliation":[{"name":"The Functional Gut Clinic London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Wernisch","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit<!--<institution-id institution-id-type=\"Ringgold\">2152<\/institution-id>--> Cambridge University Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"di Pietro","sequence":"additional","affiliation":[{"name":"MRC Cancer Unit University of Cambridge Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62171-0"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.045"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.117"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.50"},{"key":"e_1_2_12_7_2","first-page":"97","article-title":"Perendoscopic real-time assessment of pH improves detection of gastric preneoplastic conditions","volume":"59","author":"Pezzicoli G","year":"2013","journal-title":"Minerva Gastroenterol Dietol"},{"key":"e_1_2_12_8_2","unstructured":"NICE.Guidance. Appendix A: Dosage information on proton pump inhibitors gastro-oesophageal reflux disease 6and dyspepsia in adults: investigation and management https:\/\/www.nice.org.uk\/guidance\/cg184\/chapter\/Appendix-A-Dosage-information-on-proton-pump-inhibitors(accessed 12 August 2019)."},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.200063"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8698230"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.08.032"},{"key":"e_1_2_12_12_2","first-page":"110","article-title":"Pilot randomized crossover study comparing the efficacy of transnasal disposable EndoSheath with standard endoscopy to detect Barrett's esophagus","volume":"48","author":"Shariff MK","year":"2016","journal-title":"Endoscopy"},{"key":"e_1_2_12_13_2","first-page":"1532","article-title":"Optimal dosing of omeprazole 40 mg daily: Effects on gastric and esophageal pH and serum gastrin in healthy controls","volume":"91","author":"Kuo B","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2006.00619.x"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00288-5"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12666"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000221146"},{"key":"e_1_2_12_18_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-230X-8-15","article-title":"Time esophageal pH\u2009<\u20094 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors","volume":"8","author":"Gerson LB","year":"2008","journal-title":"BMC Gastroenterol"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.139.5.547"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640619880362","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1177\/2050640619880362","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640619880362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T06:33:47Z","timestamp":1693722827000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1177\/2050640619880362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1177\/2050640619880362"],"URL":"https:\/\/doi.org\/10.1177\/2050640619880362","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}